30 closest matches · ranked by relevance
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Systemic Allergic Reaction
Primary: Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine — 0.125 Proportion of participants
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Peanut Hypersensitivity · Food Hypersensitivity · Food Allergy
Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg
Allergy Drug · Allergic Reaction · Pediatric
Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Allergy · Asthma
Primary: Proportion of Participants Who Discontinue Study — 7.1 Percentage of Participants
Allergic Asthma
Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants
Allergic Rhinitis · Conjunctivitis
Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Anaphylaxis · Hypotension · Bronchospasm
Primary: Reduction in the Number and Timing of Anaphylactic Events in Subjects With a History of Frequent Idiopathic Anaphylaxis. — 32; 6 percentage of change of events
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Hymenoptera Venom Allergy · Antihypertensive Treatment
Primary: Frequency of Side Effects (=Systemic Reaction, SR) During Venom Immunotherapy (VIT) — 19; 74 Participants — p=0.25
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Allergic Rhinitis · Conjunctivitis
Primary: Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo — 7.503; 8.498 Scores on a Scale — p=0.0497
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
Asthma
Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
Peanut Allergy
Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
Food Hypersensitivity · Hypersensitivity · Immediate Hypersensitivity
Primary: Percent of Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral…
Allergic Rhinitis · Asthma · Food Allergy
Primary: Wheal Response — 6.8 mm
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Rhinitis · Asthma · Allergy
Primary: Change in Symptoms Score After Nasal Allergen Challenge — -5; -4; -1 score on a scale